Author(s): Grogl M, Schuster BG, Ellis WY, Berman JD
Abstract Share this page
Abstract Cutaneous leishmaniasis is presently treated with 20 days of parenteral therapy with a frequently toxic drug (antimony). Topical formulations of paromomycin (15\%) plus methylbenzethonium chloride (MBCL, 12\%) or plus urea (10\%) in soft white paraffin have been tested for Old and New World disease in humans. We compared the efficacy of a new topical formulation, WR 279,396 (paromomycin [15\%] plus gentamicin [0.5\%]) to the clinical formulations in the treatment of cutaneous disease in BALB/c mice. Sixty-day-old lesions were treated twice a day for 10 days, and the response to therapy was determined over a further 70 days. For ulcers due to Leishmania major or to Leishmania mexicana, 100\% of lesions in the WR 279,396 group healed by day 20 after therapy and did not relapse by day 70; 83\% of lesions healed without relapse in the paromomycin-MBCL group. In the paromomycin-urea group, 100\% of L. major lesions healed by day 30 but 30\% relapsed. For ulcers due to Leishmania panamensis or Leishmania amazonensis, all lesions treated with WR 279,396 healed and did not relapse; < 50\% of lesions treated with paromomycin-MBCL healed by day 30, and all lesions relapsed by day 70. In addition to being active, WR 279,396 was not toxic in this model and appears to have a cosmetic effect (promoting hair growth, healing, and limiting the size of the scar).
This article was published in J Parasitol
and referenced in Journal of Computer Science & Systems Biology